Significance of angiogenesis in cancer therapy

British Journal of Surgery

Volumn 85, Issue 8, 1998, Pages 1044-1055

  McNamara, D A ^a,b   Harmey, J H ^a   Walsh, T N ^a   Redmond, H P ^a   Bouchier Hayes, D J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTOXIN; INTEGRIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADJUVANT THERAPY; ANGIOGENESIS; CANCER SURGERY; CYTOKINE RELEASE; HUMAN; LITERATURE; MEDICAL INFORMATION; METASTASIS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

GROWTH SUBSTANCES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0031856412     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00816.x     Document Type: Review

References (215)

1. 3. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, Pennsylvania: Lippincott, 1996: 69-87.
2. Noden DM. Embryonic origins and assembly of blood vessels. Am Rev Respir Dis 1989; 140: 1097-103.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
4. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9.
5. Folkman J, Shinn Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
6. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974; 34: 997-1004.
7. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Nat Cancer Inst 1996; 88: 1146-51.
8. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
9. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
10. Macchiarini P, Fontanini G, Hardin MJ, Squartini F. Angelletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992; 340: 145-6.
11. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995; 36: 193-204.
12. Heimann R, Ferguson D, Powers C, Recant WM, Wcichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996: 88: 1764-9.
13. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
14. Costello P, McCann A, Carney DN, Dervan PA. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995; 26: 1181-4.
15. Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 29A: 1141-5.
16. Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eut J Cancer 1995; 31A: 1101-4.
17. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
18. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995: 1: 27-31.
19. Jiang WG, Puntis MCA, Hallett MB. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg 1994; 81: 1576-90.
20. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3: 505-9.
21. Walker RA. Angiogenesis and breast cancer prognosis - a continuing issue. J Pathol 1996; 180: 6-7.
22. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997; 3: 437-42.
23. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995; 159: 113-60.
24. Nehls V, Schuchardt E, Drenckhahn D. The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc Res 1994; 48: 349-63.
25. Lee JY, Murphy SM, Scanlon EF. Effect of trauma on implantation of metastatic tumor in bone in mice. J Surg Oncol 1994; 56: 178-84.
26. Bitterman PB, Rennard SI, Adelberg S, Crystal RG. Role of fibronectin as a growth factor for fibroblasts. J Cell Biol 1983; 97: 1925-32.
27. Fava RA, McClure DB. Fibronectin-associated transforming growth factor. J Cell Physiol 1987; 131: 184-9.
28. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 303-24.
29. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996; 149: 1851-69.
30. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-20.
31. Nagy JA, Herzberg KT, Masse EM, Zientara GP, Dvorak HF. Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res 1989; 49: 5448-58.
32. Donovan D, Harmey JH, Redmond HP, Bouchier-Hayes D. Ascites revisited: a novel role for tamoxifen. Eur J Surg Oncol 1997; 23: 570.
33. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 2: 167-8.
34. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120-2.
35. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
36. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
37. Aiello LP, Avery RL, Arrigg BA, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
38. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
39. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H. Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Opthalmic Res 1995; 27: 48-52.
40. Polverini PJ. Macrophage-induced angiogenesis: a review. In: Sorg C, ed. Macrophage-derived Cell Regulatory Factors. Basel: Karger, 1989: 54-73.
41. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996; 98: 482-9.
42. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55: 1189-93.
43. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410-22.
44. Harmey J, Dimitriadis E, Redmond HP, Bouchier-Hayes D. Macrophage production of vascular endothelial growth factor (VEGF) is differentially regulated by hypoxia and transforming growth factor β-1. Ann Surg Oncol 1998; 5: 271-8.
45. Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes D. Elevated vascular endothelial growth factor in breast cancer: a proposed mechanism. Surgical Forum 1996; XLVII: 522-4.
46. Knighton DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, Bands MJ. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 1983; 221: 1283-5.
47. van Netten JP, Ashmed BJ, Cavers D, Fletcher C, Thornton IG, Antonsen BL et al. 'Macrophages' and their putative significance in human breast cancer. Br J Cancer 1992; 66: 220-1 (Letter).
48. Mantovani A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 1994; 71: 5-16.
49. Welch DR, Schissel DJ, Howley RP, Aeed PA. Tumorelicited polymorphonuclear cells, in contrast to 'normal' circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci USA 1989; 86: 5859-63.
50. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-5.
51. Fcrrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127-37.
52. Marme D. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. World J Urol 1996; 14: 166-74.
53. de Vries C, Escobedo JA, Ueno H, Houck N, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.
54. Terman BI, Dougher-Vermazen NM, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor.. Biochem Biophys Res Commun 1992; 187: 1579-86.
55. Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995; 217: 721-7.
56. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 1995; 270: 31189-95.
57. Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Opthalmol Vis Sci 1996; 37: 2165-76.
58. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3: 158-64.
59. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial cell growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992; 359: 843-5.
60. Minchenko A, Salaceda S, Bauer T, Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994; 40: 35-9.
61. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333-40.
62. Grone HJ, Simon M, Grone EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995; 177: 259-67.
63. Hashimoto E, Kage K, Ogita T, Nakaoka T, Matsuoka R, Kira Y. Adenosine as an endogenous mediator of hypoxia for induction of vascular endothelial growth factor mRNA in U-937 cells. Biochem Biophys Res Commun 1994; 204: 318-24.
64. Brogi E, Schatterman G, Wu T, Kim EA, Varticovski L, Keyt B et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996; 97: 469-76.
65. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
66. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
67. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa D, Sasazuki T et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-80.
68. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Nat Acad sci U S A 1997; 94: 861-6.
69. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56: 172-81.
70. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401.
71. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes DJ. Transforming growth factor β-1 regulation of vascular endothelial growth factor production by breast cancer cells. Ann Surg Oncol 1997; 4: 621-7.
72. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993; 90: 10705-9.
73. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J et al. Inhibition of vascular endothelial growth factor prevents retinal-ischemia induced iris neovascularization in a nonhuman primate. Arch Opthalmol 1996; 114: 66-71.
74. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989; 109: 1-6.
75. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92 (Suppl II): II 365-71.
76. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic tibroblast growth factor, a mitogen that promotes their own growth. Nature 1987; 325: 257-9.
77. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibroscarcoma. Cell 1991; 66: 1095-104.
78. Biro S, Yu Z-X, Fu Y-M, Smale G, Sasse J, Sanchez J et al. Expression and subcellular distribution of basic fibroblast growth factor are regulated during migration of endothelial cells. Circ Res 1994; 74: 485-94.
79. Jackson CL, Reidy MA. Basic fibroblast growth factor: its role in the control of smooth muscle cell migration. Am J Pathol 1993; 143: 1024-31.
80. Lindner V, Reidy MA. Proliferation of smooth muscle after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 1991; 88: 3739-43.
81. Gross JL, Herblin WF, Dvorak BA, Czerniak P, Diamond MD, Sun T et al. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993; 85: 121-31.
82. Danesi R, Del Bianchi S, Soldani P, Campagni A, La Rocca RV, Myers CE et al. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 1993; 68: 932-8.
83. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51: 6180-4.
84. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
85. Thompson JA, Anderson KD, DiPietro JM, Zwiebel JA, Zametta M, Anderson WF et al. Site-directed neovessel formation in vivo. Science 1988; 241: 1349-52.
86. Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Progress in Growth Factor Research 1989; 1: 207-35.
87. Thomas KA, Gimenez-Gallego G, Di Salvo J, Linemeyer D. Kely L, Menke J et al. Structure and activities of acidic fibroblast growth factor. In: Rifkin DB, Klagbrun M, eds. Current Communications in Molecular Biology: Angiogenesis Mechanisms and Pathobiology. Cold Spring Harbor, New York: Cold Spring Harbor Laboratories, 1987: 9-12.
88. Miyazono K, Okabe T, Urabe A, Takaku F, Heldin CH. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987; 262: 4098-103.
89. Usuki K, Heldin N-E, Miyazono K, Ishikawa F, Takaku F, Westermark B et al. Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture. Proc Natl Acad Sci U S A 1989; 86: 7427-31.
90. Finnis C, Dodsworth N, Pollitt CE, Carr G, Sleep D. Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. Eur J Biochem 1993; 212: 201-10.
91. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992; 7: 261-6.
92. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-39.
93. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997; 57: 570-72.
94. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K et al. Angiogenic factor. Nature 1992; 356: 668 (Letter).
95. O'Brien TS, Harris AL. Angiogenesis in urological malignancy. Br J Urol 1995; 76: 675-82.
96. Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 1997; 76: 689-93.
97. Thompson AM, Kerr DJ, Steel CM. Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer 1991; 63: 609-14.
98. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986; 83: 4167-71.
99. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol 1987; 105: 1039-45.
100. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF β-1 and TGF β-2 or exogenous addition of TGF-β 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108: 985-1002.
101. Pierce GF, Tarpley JE, Yanagihara D, Mustoe TA, Fox GM, Thomason A. Platelet-derived growth factor (BB homodimer), transforming growth factor-β1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair. Am J Pathol 1992; 140: 1375-88.
102. Pepper MS, Vassali JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-β 1 on in vitro angiogenesis. Exp Cell Res 1993; 204: 356-63.
103. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 1153-5.
104. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature -a potential therapeutic target. Br J Cancer 1995; 72: 257-67.
105. O'Sullivan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993; 342: 148-9.
106. Murthy MS, Scanlon EF, Silverman RH, Goodheart CR, Goldschmidt RA, Jelachich ML. The role of fibronectin in tumor implantation at surgical sites. Clin Exp Metastasis 1993; 11: 159-73.
107. 3 during angiogenesis. J Clin Invest 1996; 98: 426-33.
108. 3 for angiogenesis. Science 1994; 264: 569-71.
109. Le J, Vilcek J. Biology of disease. Tumour necrosis factor and interleukin-1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234-48.
110. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329: 630-2.
111. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 5277-81.
112. Mattsby-Baltzer I, Jokobsson A, Sorbo J, Norrby K. Endotoxin is angiogenic. Int J Exp Pathol 1994; 75: 191-6.
113. Watson RW, Redmond HP, Bouchier-Hayes D. Role of endotoxin in mononuclear phagocyte-mediated inflammatory responses. J Leukoc Biol 1994; 56: 95-103.
114. Li WW, Grayson G, Folkman J, D'Amore PA. Sustained-release endotoxin. A model for inducing corneal neovascularization. Invest Ophthalmol Vis Sci 1991; 32: 2906-11.
115. Pidgeon G, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes D. The effect of surgery and endotoxin on tumour growth and angiogenesis. Ir J Med Sci 1997; 166: 8.
116. Raugi GJ, Mumby SM, Abott-Brown D, Bornstein P. Thrombospondin: synthesis and secretion by cells in culture. J Cell Biol 1982; 95: 351-4.
117. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997; 22: 251-6.
118. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56: 345-55.
119. Bouck N. Tumour angiogenesis: the role of oncogenes and tumour suppressor genes. Cancer Cells 1990; 2: 179-85.
120. BenEzra D, Griffin BW, Maftzir G, Aharonov O. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophthalmol Vis Sci 1993; 34: 3601-8.
121. O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
122. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-53.
123. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
124. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia. Nature 1989; 339: 58-61.
125. Brem SS, Jensen HM, Gullino PM. Angiogenesis as a marker for preneoplastic lesions of the human breast. Cancer 1978; 41: 239-44.
126. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977; 195: 880-2.
127. Contrino J, Hair G, Kreutzer D, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-15.
128. Sager R. Tumour suppressor genes: the puzzle and the promise. Science 1989; 246: 1406-12.
129. Whalen GF. Solid tumours and wounds: transformed cells misunderstood as injured tissue? Lancet 1990; 336: 1489-92.
130. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
131. Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen: degradation by migrating endothelial cells. Science 1983; 221: 281-3.
132. Postlewaithe AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med 1987; 165: 251-6.
133. Liotta LA, Stracke ML. Tumor invasion and metastases: biochemical mechanisms. Cancer Treat Res 1988; 40: 223-38.
134. Liotta LA, Saidel G, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36: 889-94.
135. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989; 948: 305-26.
136. Fidler IJ, Gerstein DM, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res 1978; 28: 149-250.
137. Nicholson G. Cancer metastasis. Sci Am 1979; 240: 66-76.
138. Ammirati M, Rao LN, Murthy MS, Buchmann T. Goldschmidt RA, Scanlon EF. Partial nephrectomy in mice with milliwatt carbon dioxide laser and its influence on experimental metastasis. J Surg Oncol 1989; 41: 153-9.
139. Murthy MS, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T, Scanlon EF. Influence of surgical trauma on experimental metastasis. Cancer 1989; 64: 2035-44.
140. Skipper D, Jeffrey MJ, Cooper AJ, Alexander P, Taylor I. Enhanced growth of tumour cells in healing colonic anastomoses and laparotomy wounds. Int J Colorectal Dis 1989; 4: 172-7.
141. Baum M, Badwe RA. Does surgery influence the natural history of breast cancer? In: Wise L, Johnson J Jr, eds. Breast Cancer: Controversies in Management. Armonk, New York: Futura Publishing, 1994: 61-9.
142. Baum M. Breast cancer: a challenge to the contemporary paradigm. Acta Oncol 1996; 35(Suppl 8): 3-6.
143. Watson RW, Redmond HP, McCarthy J, Burke PE, Bouchier-Hayes D. Exposure of the peritoneal cavity to air regulates early inflammatory responses to surgery in a murine model. Br J Surg 1995; 82: 1060-5.
144. McNamara DA, Pidgeon G, Harmey J, Redmond HP, Walsh TN, Bouchier-Hayes DJ. Exposure to lipopolysaccharide elicits vascular endothelial growth factor production by macrophages and tumour cells. Gastroenterology 1998; (in press).
145. Redmond HP, Watson RW, Houghton T, Condron C, Watson RG, Bouchier-Hayes D. Immune function in patients undergoing open vs laparoscopic cholecystectomy. Arch Surg 1994; 129: 1240-6.
146. Da Costa ML, Redmond HP, Bouchier-Hayes DJ. Increased tumor establishment and growth after laparotomy vs laparoscopy. Arch Surg 1996; 131: 1003 (Letter).
147. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920-5.
148. Teicher BA, Holden SA, Ara G, Northey D. Response of the FSal1 fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res 1993; 13(6A): 2101-6.
149. Teicher BA, Ara G, Menon K, Schaub RG. In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer 1996; 65: 80-4.
150. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification of and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
151. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814-19s.
152. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995; 36: 109-18.
153. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989; 320: 1211-12.
154. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
155. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349(Suppl II): 13-15.
156. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
157. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamura T, Brem H et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7.
158. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5.
159. Malone TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-9.
160. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-147O. Nat Med 1997; 3: 443-6.
161. Effert PJ, Gastl G, Strohmeyer T. Current and future strategies to block tumor angiogenesis, invasion, and metastasis. World J Urol 1996; 14: 131-40.
162. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. J Pediatr Surg 1993; 28: 445-51.
163. Brem H, Gresser I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 1993; 28: 1253-7.
164. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of puylmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197-200.
165. Egawa S, Tsutsumi M, Konishi Y, Kohari M, Matsuno S, Nagasaki K et al. The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR. Gastroenterology 1995; 108: 1526-33.
166. Wu J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer. Anticancer Res 1996; 16: 2233-9.
167. Hanahan DA. A flanking attack on cancer. Nat Med 1998; 4: 13-14.
168. Stout AJ, Gresser I, Thompson WD. Inhibition of wound healing in mice by local interferon alpha/beta injection. Int J Exp Pathol 1993; 74: 79-85.
169. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Nat Cancer Inst 1995; 87: 581-6.
170. Takano S, Gatley S, Neville ME, Herblin WF, Gross JL, Engelhard H et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54: 2654-60.
171. McNamara DA, Harmey J, Wang JH, Donovan D, Kaye E, Walsh TN et al. Tamoxifen is antiangiogenic in vitro and attenuates VEGF-mediated angiogenesis in vivo. Ir J Med Sci 1998; (in press).
172. Sledge GW Jr. Implications of the new biology for therapy in breast cancer. Semin Oncol 1996; 23(1Suppl 2): 76-81.
173. Martiny-Baron G, Marme D. VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr Opin Biotechnol 1996; 6: 675-80.
174. Blau H, Khavari P. Gene therapy: progress, problems, prospects. Nat Med 1997; 3: 612-13.
175. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa 2a for life-threatening hemangiomas in infancy. N Engl J Med 1992; 326: 1456-63.
176. Klein G. The approaching era of the tumor suppressor genes. Science 1987; 238: 1539-45.
177. Jouanneau J, Moens G, Montesano R, Thiery JP. FGF-1 hut not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation. Growth Factors 1995; 12: 37-47.
178. Camussi G, Montrucchio G, Lupia E, De Martino A, Perona L, Arese M et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 1995; 154: 6492-501.
179. Gleave ME, Hsieh JT, Wu HC, Hong SJ, Zhau HE, Guthrie PD et al. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res 1993; 53: 5300-7.
180. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994; 145: 1023-9.
181. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993; 4: 121-33.
182. Fan TP, Hu DE, Guard S, Gresham GA, Watling KJ Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK-1 or interleukin-1 receptor antagonists. Br J Pharmacol 1993; 110: 43-9.
183. Wojta J, Gallicchio M, Zoellner H, Filonzi EL, Hamilton JA, McGrath K. Interleukin-4 stimulates expression of urokinase-type-plasminogen activator in cultured human foreskin microvascular endothelial cells. Blood 1993; 81: 3285-92.
184. Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994; 179: 1409-15.
185. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997; 233: 231-7.
186. Moenner M, Gusse M, Hatzi E, Badet J. The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem 1994; 226: 483-90.
187. Tsoplanglou PE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993; 264: C1302-7.
188. Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995; 105: 170-6.
189. Rosen EM, Zitnik RJ, Elias JA, Bhargava MM, Wines J, Goldberg ID. The interaction of HGF-SF with other cytokines in tumor invasion and angiogenesis. EXS 1993; 65: 301-10.
190. Bikfalvi A, Han ZC. Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia 1994; 8: 523-9.
191. Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 1995; 96: 940-52.
192. Jackson D, Volpert OV, Bouck N, Linzer DI. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 1994; 266: 1581-4.
193. Magee JC, Stone AE, Oldham KT, Guice KS. Isolation, culture, and characterization of rat lung microvascular endothelial cells. Am J Physiol 1994; 267: L433-641.
194. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995; 372: 83-7.
195. Hildenbrand R, Dilger I, Horlin A, Stutte HJ. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol Res Pract 1995; 191: 403-9.
196. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 1995; 108: 797-809.
197. Ziehe M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94: 2036-44.
198. Mitchell CA, Davies MJ, Grounds MD, McGeachie JK, Crawford GJ, Hong Y et al. Enhancement of neovascularization in regenerating skeletal muscle by the sustained release of erucamide from a polymer matrix. J Biomater Appl 1996; 10: 230-49.
199. Kobayashi S, Okabe M, Kimura I, Kimura M. Interferon-gamma-activated macrophages release interleukin-1 alpha to increase tube formation from endothelial cells of rat aorta. Immnunopharmacology 1995; 31: 93-101.
200. Angiolillo Al, Sgadari C, Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci 1996; 795: 158-67.
201. Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995; 55: 1499-504.
202. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-9.
203. Stricter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J et al. Role of C-X chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995; 57: 752-62.
204. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A et al. Dominant negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615-20.
205. Fotsis T, Zhang Y, Pepper MS, Aldercreutz H, Montesano R, Nawroth PP et al. The endogenous oestrogen metabolite 2-methoxyoestradiole inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237-9.
206. Takigawa M, Nishida Y, Suzuki F, Kishi J, Yamashita K, Hayakawa T. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun 1990; 171: 1264-71.
207. Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993; 53: 224-6.
208. Thurman GB, Page DL, Wamil BD, Wilkinson LE, Kasami M, Hellerqvist CG. Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM 101 (GBS toxin). J Cancer Res Clin Oncol 1996; 122: 549-53.
209. Nguyen NM, Lehr JE, Pienta KJ. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 1993; 13: 2143-7.
210. Hu DE, Fan TP. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br J Pharmacol 1995; 114: 262-8.
211. Hori Y, Hu DE, Yasui K, Smither RL, Gresham GA, Fan TP. Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants. Br J Pharmacol 1996; 118: 1584-91.
212. Yamamoto T, Terada N, Nishizawa Y, Petrow V. Angiostatic activities of medroxyprogesterone acetate and its analogues. Int J Cancer 1994; 56: 393-9.
213. Yoon TJ, Yoo YC, Choi OB, Do MS, Khang TB, Lee SW et al. Inhibitory effect of Korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non-haematogenous tumour cells in mice. Cancer Lett 1995; 97: 83-91.
214. Tarnawski A, Hollander D, Stachura J, Sarfeh IJ, Gergely H, Krause WJ et al. Angiogenic response of gastric niucosa to ethanol injury is abolished by indomethacin. Gastroenterology 1989; 96: A505 (Abstract).
215. Lala PK, Al-Mutter N, Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 1997; 73: 371-80.